Summary: Venous access has been a problem in the every day oncology. Antineoplastic agents, adminisiered over months or years, common y result in sclerosis of available surface vessels. Previous approaches, such as arteriovenous fistulas, grafts, or percutaneous catheters, have not gained widespread acceptability. Only the Hickman katetr is extremely useful in the management of acute leukemia and in bone marrow transplantation patients. Totally implantable venous acces system represents a potential improvement in venous approach. We reported revue of the development of central venous access device, up-to-date possibilities and trends of this subject. We demonstrate first experiences with 11 IMPLANT0F1X® devices, a totally implantable venous access system. The ports were in place for an average of 189 days (range 37-189 days), for a total of 1001 catheter days. A total of 4 complications occured in 4 patients. There was 1 case of venous trombosis, 1 case of catheter occlusion, 1 case of extravasation of chemotherapy agents and 1 case of early bleeding after the implantation. Both patients and nursing staff showed a very high degree of satisfaction with this system. Safety profile, acceptability to patients and the improving quality of life identify it as a significant advantage for the management of oncology patients with poor venous access.
Contemporary possibilities to solve a long-term venous approach in oncological patients
